BEAM - CIK 0001745999
Beam Therapeutics Inc. trades as BEAM and has a market capitalization of $3.08 B, making it the #1781 largest US-listed company by market value. In its fiscal 2025 annual report the company posted revenue of $139.74M, up 120.0% from the prior year and net income of -$79.99M. This page tracks Beam Therapeutics Inc. through 488 SEC filings, with financial statements and metrics updated as new reports are filed.
Over the last 6 fiscal years Beam Therapeutics Inc.'s revenue grew from $18.00K to $139.74M, a compound annual growth rate of 345.0%. Net profit margin expanded from -435144.4% to -57.2% over the same period - every figure below comes from the company's audited annual filings.
| Filing | Type | Filed |
|---|---|---|
| Quarterly report | 10-Q | 2026-05-07 |
| Major company event | 8-K | 2026-05-07 |
| SCHEDULE 13G | - | 2026-04-29 |
| Annual report to shareholders | ARS | 2026-04-17 |
| Proxy materials | DEFA14A | 2026-04-17 |
| Proxy statement | DEF 14A | 2026-04-17 |
| Insider sale notice | 144 | 2026-04-14 |
| Insider trade | 4 | 2026-04-06 |
Beam Therapeutics to Present at 2026 RBC Capital Markets Global Healthcare Conference | Beam Therapeutics
Beam Therapeutics to Present Updated Biomarker Data from Phase 1/2 BEACON Trial Further Underscoring Risto-cel’s Ability to Restore Red Blood Cell Health and Function in Sickle Cell Disease at EHA2026 | Beam Therapeutics
Beam Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Updates | Beam Therapeutics
Beam Therapeutics Announces Publication of BEACON Phase 1/2 Data for risto-cel in Patients with Sickle Cell Disease (SCD) in The New England Journal of Medicine | Beam Therapeutics
The largest companies sharing Beam Therapeutics Inc.'s SEC industry classification (biological products, (no diagnostic substances)).
Beam Therapeutics Inc. (BEAM) has a market capitalization of $3.08 B as of 2026-06-10, ranking #1781 among US-listed companies.
Beam Therapeutics Inc. reported revenue of $139.74M for fiscal year 2025, an increase of 120.0% year over year.
In its latest fiscal year Beam Therapeutics Inc. reported a net loss of $79.99M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.
Beam Therapeutics Announces Compelling Updated Clinical Data from the Ongoing Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) to Support Advancement to Pivotal Development | Beam Therapeutics